Your session is about to expire
← Back to Search
40 mg PRAX-114 for Post-Traumatic Stress Disorder
Study Summary
This trial is a 4-week study of a new drug for PTSD, with an 8-week extension for those who want to continue.
- Post-Traumatic Stress Disorder
- Stress Disorders
- Trauma and Stressor Related Disorders
- Psychiatric Disorder
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 24 Patients • NCT05021978Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Who meets the requirements to be a participant in this research?
"Eligible patients for this clinical trial should present with moral injury and be between 18-65 years old. There are only 11 spots available."
Can patients who are over the age of 50 participate in this trial?
"This particular study is only open to people who are 18-65. Out of the 1323 clinical trials, 371 are for people under 18 and 1052 are for people over 65."
Are there numerous test facilities in Canada for this research project?
"17 clinical trial sites are presently running this study. They are located in cities such as Little Rock, Allentown, and Phoenix. If you are interested in participating, it would be best to select the trial site nearest you to avoid excessive travel."
40 mg PRAX-114 is an FDA-approved medication, correct?
"PRAX-114's safety was given a score of 2. This is due to it being a Phase 2 medication, so while there is data suggesting it is safe, there is none yet affirming that it is an effective treatment."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger